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Abstract
NontypeableHaemophilus influenzae (NTHi) cause significant disease, including otitis media
in children, exacerbations of chronic obstructive pulmonary disease, and invasive disease in
susceptible populations. No vaccine is currently available to prevent NTHi disease. The inter-
actions of NTHi and the human host are primarily mediated by lipooligosaccharide and a com-
plex array of surface-exposed proteins (SEPs) that act as receptors, sensors and secretion
systems.We hypothesized that certain SEPs are present in all NTHi strains and that a subset
of these may be antibody accessible and represent protective epitopes. Initially we used 15
genomic sequences available in the GenBank database along with an additional 11 genomic
sequences generated by ourselves to identify the core set of putative SEPs present in all
strains. Using bioinformatics, 56 core SEPs were identified. Molecular modeling generated
putative structures of the SEPs fromwhich potential surface exposed regions were defined.
Synthetic peptides corresponding to ten of these highly conserved surface-exposed regions
were used to raise antisera in rats. These antisera were used to assess passive protection in
the infant rat model of invasive NTHi infection. Five of the antisera were protective, thus dem-
onstrating their in vivo antibody accessibility. These five peptide regions represent potential
targets for peptide vaccine candidates to protect against NTHi infection.
Introduction
Nontypeable Haemophilus influenzae (NTHi) cause both invasive and noninvasive infections,
including otitis media, bacteremia and exacerbations of chronic obstructive pulmonary disease
[1–4] and are a significant public health burden. The most common infection caused by NTHi
is acute otitis media (AOM). AOM accounts for 33% of visits by children to health care centers
and is the most frequent reason children receive antibiotics [5]. The incidence of AOM peaks
between 6 and 12 months of life; almost 100% of children in developing communities and two-
thirds of children in developed communities experience their first episode of OM by one year
of age [6]. By age 3 years, 80% of children in the U.S. have experienced at least one episode, and
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40% have three or more recurrent episodes [7]. Compared to children without AOM those
with acute AOM had 2 additional office visits, 0.2 additional emergency room visits and 1.6
additional prescriptions per year. These visits lead to an estimated incremental increase in out-
patient healthcare costs of $314 per year per child [8].
Historically, Streptococcus pneumoniae were the most common AOM isolate, and NTHi
were the second most common [5]. Since the introduction of the PCV-7 S. pneumoniae vaccine
in 2000, the number of cases of OM attributable to S. pneumoniae has markedly decreased
[5,9]. However, the overall number of cases of OM has been reduced about 7% with the PCV-7
vaccine [5,10]. The reduction in the incidence of S. pneumomiae OM has resulted in an
increase in the proportion of OM attributable to NTHi, and NTHi is now reported as the pre-
dominant cause of AOM [5,11,12].
In previous decades, greater than 95% of the cases of invasive disease caused byH. influen-
zae were due to strains with the type b capsule. However, vaccines based on the type b capsular
polysaccharide have virtually eliminated such infections in regions where the vaccine is exten-
sively used [13]. Nevertheless, NTHi strains continue to cause invasive disease principally in
perinatal infants, young children, and those older than 65 years [1,14].
Several lines of evidence suggest that prevention of AOM due to NTHi is possible [15–17].
First, AOM is largely a disease of infants in whom the serum and mucosal antibodies directed
against common pathogens are low [18]. Second, OM-prone children have lower levels of
serum antibodies than healthy age-matched controls [19,20]. Third, individuals with immuno-
deficiencies are predisposed to repeated NTHi infections [21]. In addition, breast-feeding is
associated both with a reduced frequency of AOM, and higher levels of serum antibodies
against NTHi in the nursing infant [22].
Evidence from animal studies also supports the possibility of preventing AOM caused by
NTHi. For example, it is possible to protect against challenge by pre-immunization with pilins
from the challenge isolate, although cross protection against unrelated isolates was not devel-
oped [23]. Similarly, peptide motifs of the pilins were shown to protect, but only against
homologous challenge [24]. This lack of cross protection presumably results from known
sequence heterogeneity of the pilin proteins. Other studies have assessed protection afforded
by antibodies to a number of virulence factors, including major and minor outer-membrane
proteins (OMPs) and lipooligosaccharide [17]. Finally, an 11-valent S. pneumoniae vaccine
usingH. influenzae protein D as a carrier molecule afforded partial protection (a reduction of
35%) against NTHi OM in a human clinical trial [16,25,26].
Non-toxic, broadly cross-reactive immunoprotective NTHi antigens have yet to be identified, and
there are significant obstacles to be addressed before a comprehensive vaccine can be developed for
NTHi. Because of the known heterogeneity of surface associated moieties in the NTHi [27], an effi-
cacious vaccine may require a multi-component design. While a few vaccine candidates have been
identified, the development, production and clinical testing of vaccines against NTHi are still lack-
ing [17]. To date, highly immunogenic surface components that elicit protective antibodies against
mucosal infections by all strains of NTHi in the age-appropriate population have not been identi-
fied. As a first step to identifying suitable protective epitopes, we used a genomic analysis to identify
conserved surface-exposed peptides and tested 10 of these for their in vivo antibody accessibility.
Materials and Methods
Bacterial strains and growth conditions
The NTHi strain R2866 was isolated from the blood of an immunocompetent child with clini-
cal signs of meningitis subsequent to AOM [28]. We have previously utilized this strain in the
infant rat model of invasiveH. influenzae disease [29].
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NTHi strain sequences used to generate alignments included sequences available through
GenBank as well as multiple strains sequenced in house. Sequences obtained through GenBank
were from the following strains: 3655, 6P18H1, 7P49H1, PittAA, PittEE, PittGG, PittHH,
PittII, R3021, R2846, R2866, 22.1–21, 22.4–21, 86-028NP and NT127. Strains sequenced in
house were from our laboratory collection and included several selected from those typed
by electrophoretic mobility of 15 metabolic enzymes [30]. These strains were selected to repre-
sent the breadth of the species as defined by electrophoretic type (ET) and were HI1373,
HI1374, HI1388, HI1394, HI1408, HI1417 and HI1426 representing, respectively, ET’s 13, 26,
43, 53, 68, 77 and 86. An additional four clinical isolates selected from our collection were also
sequenced: HI1722, HI1974, HI2114 and HI2116. Isolates of H. influenzae were routinely
maintained on chocolate agar with bacitracin at 37°C. Broth cultures of H. influenzae were
grown in brain heart infusion (BHI) agar supplemented with 10 μg/ml heme and 10 μg/ml
β-NAD (supplemented BHI; sBHI).
Genome sequencing of NTHi strains
Chromosomal DNA was isolated from bacteria recovered from fresh 12 hour broth cultures
using the DNeasy Blood and Tissue Kit (Qiagen) as described by the manufacturer. Genome
sequences of the NTHi strains were determined at the Laboratory for Molecular Biology and
Cytometry Research, University of Oklahoma Health Sciences Center.
NTHi samples were prepared using 50-ng of total genomic DNA according to Nextera
DNA library kit protocols (Illumina Inc). Samples were indexed according to standard proto-
cols so that they could be pooled together and sequenced simultaneously in a single run on the
Illumina MiSeq using paired-end 150-bp (300 cycle) chemistry. Prior to sequencing, all librar-
ies were run individually on the Agilent High Sensitivity DNA chip to confirm library quality
and average insert size. Samples were pooled in equimolar amounts and 8pM of the pool was
run on the sequencer. Per Illumina’s recommendation, phiX control was spiked into the library
pool prior to loading for quality control purposes (5–10% phiX). Thirty to forty million reads
total were collected for each run. Raw sequence data were aligned to a reference isolate using
CLC Genomics Workbench (CLC Bio.) to identify single-nucleotide polymorphisms (SNPs) as
well as regions with insertions or deletions (indels) or raw data files were assembled using CLC
de novo assembly parameters.
The genome sequences generated herein were deposited in Genbank. Sequenced strains and
corresponding accession numbers are as follows HI1373 (LFDP00000000), HI1374 (LFDO00000000),
HI1388 (LFDN00000000), HI1394 (LFDM00000000), HI1408 (LFDJ00000000), HI1417
(LFDK00000000), HI1426 (LFDL00000000), HI1722 (LFFU00000000), HI1974 (LFFT00000000),
HI2114 (LFFR00000000), and HI2116 (LFFS00000000).
Identification of SEPs present in all NTHi strains
Initially, the complement of putative surface-exposed proteins (SEPs) of the isolate NTHi
86-028NP was determined based on the reported annotation of this isolate [31]. For the pur-
poses of this paper SEPs include characterized and putative OMPs as well as other secreted
proteins. Hypothetical proteins were individually examined to determine the presence of
leader sequences and/or other indicators that they may be secreted or membrane bound. All
identified proteins were then used to query the presence of homologs in the other sequenced
NTHi. Absence of a homolog in any of the sequenced NTHi excluded that protein from further
consideration. Once each core SEP was identified, Geneious software was used to perform
sequence alignments with all the known homologs of a given protein in all the available NTHi
genomes.
Protective NTHi Peptides
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Molecular modeling
The identified core SEP genes of NTHI 86-028NP were individually examined to determine
homology to other known structurally defined proteins. Structures were generated using the
Modeller algorithm [32,33], Swissmodel [34] and Phyre2 [35] via The Protein Model Portal
[36]. Putative structures were compared and visualized using Chimera to determine potentially
surface-exposed regions [37]. Proteins that shared no significant similarities with other mod-
eled proteins were examined to determine regions indicative of secondary structure using
PRED-TMBB, BOMP (β-barrel), and TMHMM (α-helix) [38–40].
Selection of peptides
From these models, predicted surface-exposed regions greater than 10 amino acids long were
selected. Multiple sequence alignments were performed with each core protein. All NTHi
homologs of each protein from both complete and partial gene and genome sequences were
used to perform these alignments. For the majority of proteins, more than 40 NTHi sequences
were aligned. External regions greater than 10 amino acids in length were further examined to
identify the degree of conservation of sequence across the NTHi. Regions with high conserva-
tion were selected as potential antigens. Some selected external loops were longer than 25
amino acids. In these cases AbDesigner [41], was used to determine the most immunogenic
region. A truncated synthetic peptide was then selected from this region for further study. Syn-
thetic peptides with>95% purity were synthesized by SynBioSci Corp., Peptide 2.0 Inc., or
Thermo Fisher. During synthesis, an aliquot of each peptide was conjugated to Keyhole limpet
haemocyanin (KLH) to facilitate immunization studies. A second aliquot was conjugated to
biotin for use in ELISA assays.
Immunization of rats
Antisera against each synthetic peptide were raised either in-house or by Thermo Fisher in two
adult Sprague-Dawley rats (~300g) using an 80 day protocol. Initially a pre-immune bleed of
approximately 1 ml was performed on each rat. On the following day rats were immunized
with 100 μg of antigen in Complete Freund’s Adjuvant. Booster injections were performed on
days 21, 42 and 62 with 50 μg of emulsified peptide preparation in Incomplete Freund’s Adju-
vant. All immunizations were administered subcutaneously to the dorsum at four to six sepa-
rate locations to minimize swelling and distress. On day 50, serum samples were collected and
antibody titers determined by peptide specific ELISA. Samples with a titer in excess of 3200
were considered suitable for protection studies and these animals were exsanguinated on day
80. Antisera from Thermo Fisher were shipped on dry ice. All antisera were stored, frozen at
-80°C until protection studies were performed.
Rat model of NTHi bacteremia
The rat model of bacteremia following intraperitoneal infection with H. influenzae was used to
compare the abilities of antisera to protect against invasive disease as previously described [42–
44]. Specified pathogen free (SPF), timed-pregnant Sprague-Dawley rats (Charles Rivers) were
received approximately five days prior to giving birth. These pregnant females were single
housed on hardwood litter with ad libitum access to water and a standard pelleted food (Purina
Lab Rodent Diet 5001). They were maintained on a 12 hour light-dark cycle in separate forced
air cubicles in a bio-containment facility (ABSL2) to prevent cross-contamination. Newborn
pups from different mothers were pooled and randomly reassigned to the mothers (n = 8–10
pups per female).
Protective NTHi Peptides
PLOS ONE | DOI:10.1371/journal.pone.0136867 September 21, 2015 4 / 16
In each experiment, cohorts of 4-day old infant rats were injected subcutaneously with
100 μl of either pre-immune serum, antiserum raised to a specific peptide, or PBS. The follow-
ing day each infant rat was challenged by intraperitoneal injection of approximately 1.5x 105
CFU of R2866. Inocula were prepared as previously described [44], and the actual infective
dosage was confirmed by quantitative plating. At 24 or 48 hours post-infection, blood samples
(50 μl) were obtained from the anesthetized infant rats (gaseous isoflourane) by cardiac punc-
ture. Bacterial titers were determined using a modified track-dilution method as previously
described [44]. All plates were incubated at 37°C for 24–48 hours to quantify CFU/ml. The
Fisher Exact Test was used to determine the statistical significance of differences in the fraction
of animals developing bacteremia in different infant rat cohorts. The Kruskal-Wallis test was
used to determine the statistical significance of differences in the mean bacteremic titers
between groups of infant rats. A P value<0.05 was taken as statistically significant.
Ethics statement
This study was performed in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocols for use
of animals in this study were reviewed and approved by the Institutional Animal Care and Use
Committee of the University of Oklahoma Health Sciences Center (Protocol numbers 13-
139-H and 14-029-I). Infected animals were monitored for signs of pain and stress at least
twice daily following infection. Signs of pain and stress are gasping, writhing behavior, immo-
bility, vocalization, hypothermia and abnormal color and were criteria for the affected animal
to be immediately euthanized. No animals were euthanized due to signs of pain or stress in the
study. All animals were euthanized by carbon dioxide inhalation following the blood draw.
Results
Immunological examination of HxuC peptides
Preliminary experiments were performed to gauge the likelihood that conserved surface-
exposed peptides represent protective epitopes. These experiments were initiated when the
available sequencedH. influenzae genomes were limited. Five complete genomes were utilized
in these studies and were the originally sequenced isolate Rd KW20, a sequenced type b isolate
10810, and three NTHi isolates (86-028NP, R2866 and R2846). The protein of interest in these
studies was the heme-hemopexin utilization protein HxuC [45,46]. The HxuC protein
sequences from the five genome-sequenced isolates, as well as several stand-alone HxuC pro-
tein sequences from additional strains, were used to perform sequence alignments. At the same
time a predicted molecular model was constructed and the putative surface-exposed regions
were determined. Five regions showing a high degree of sequence conservation were selected
for immunological examination (Table 1).
In a screening experiment the five KLH-conjugated peptides were mixed to provide a penta-
valent preparation that was used to immunize two adult rats as described. Antisera raised to
this pentavalent peptide preparation provided significant protection against NTHi bacteremia
by comparison with both PBS control and pre-immune sera from the same animals (Fig 1A).
Having demonstrated that antisera raised to the pentavalent-peptide preparation were pro-
tective we examined each of the five HxuC-derived peptides individually. Antisera specifically
against two of the peptides (HxuC1 and HxuC2) were highly protective (Fig 1). All animals
receiving antisera to HxuC2 failed to develop bacteremia, while in the cohort receiving HxuC1
antisera 2 of 10 infected animals developed bacteremia (Fig 1B). In the two animals in the Hxu-
C1-antisera treated group that developed bacteremia, the bacterial titers were approximately
Protective NTHi Peptides
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1000-fold less than control animals (Fig 1C). Antisera to the remaining three peptides from
HxuC did not provide statistically significant protection against NTHi invasive disease.
Since certain peptides derived from HxuC gave rise to protective antisera we extended our
study to include additional potentially surface-exposed proteins fromH. influenzae. Since a
highly effective vaccine is available to prevent type b disease, and type d strains are essentially
avirulent we excluded strains 10810 and Rd KW20, and instead focused on the more clinically
relevant NTHi strains.
Genome sequencing of genetically characterized diverse NTHi isolates
At the time that the HxuC peptides were selected, the number of sequenced genomes was too
low to confidently determine conservation across the NTHi of any single gene and insufficient
to determine the breadth of variation of each individual surface-exposed loop. Currently over












a Annotated name of the protein in the NTHi isolates (suffix indicates peptide number).
b Amino acid sequence of the select peptide. Residues in parentheses represent variant residues at that
single position.
doi:10.1371/journal.pone.0136867.t001
Fig 1. Protection afforded by anti-HxuC antisera in the infant rat model of NTHi bacteremia. Panel A) Percentage of infected infant rats pretreated with
pentavalent anti-HxuC antisera with detectable bacteremia 48 hours after infection. Twenty-four hours prior to infection cohorts of 10 infant rats were
pretreated with phosphate-buffered saline (PBS), pre-immune serum (PIS) or peptide-specific antiserum (PSAS). Using Fisher’s exact test to compare
percentages of bacteremic pups P = 0.0011 for PBS vs PSAS and P = 0.0198 for PIS vs PSAS. Panel B) Percentage of infected infant rats pretreated with
antisera against specific HxuC peptides with detectable bacteremia 48 hours after infection. Twenty-four hours prior to infection cohorts of infant rats were
pretreated with phosphate- buffered saline (PBS; cohort of 8 rats), HxuC1 specific antisera (HxuC1; cohort of 10 rats), or HxuC2 specific antisera (HxuC2;
cohort of 10 rats). Using Fisher’s exact test to compare percentages of bacteremic pups P = 0.0011 for PBS vs HxuC1 and P = 0.0001 for PBS vs HxuC2.
Panel C) Bacteremic titers in infected infant rats pretreated with antisera against specific HxuC peptides 48 hours after infection. Filled dots represent the
bacteremic titer in each individual animal in a cohort. The unfilled dot represents the average bacteremic titers in all members of the cohort. Values of 1 or
below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to compare bacteremic titers(means ±SD) P = 0.002 for PBS vs HxuC1
and P = 0.0004 for PBS vs HxuC2.
doi:10.1371/journal.pone.0136867.g001
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30 NTHi genome sequences are publicly available,owever, only nine of these sequences are
complete. The rest are only useful to confirm the presence and sequence of a particular gene
within the respective genome. However, since all genes may not be present, absence of an SEP
in an inadequately sequenced genome cannot exclude it from further consideration as a core
SEP. To enhance the probability that the peptide selection included regions found in all NTHi,
the genomes of an additional 11 NTHi isolates were sequenced. To assure genetic diversity, iso-
lates for sequencing were chosen from strains previously used to define the breadth of the spe-
cies by electrophoretic typing [30], as well as other NTHi clinical isolates from our culture
collection. A multi locus sequence analysis system based on five gene loci (adk, pgi, recA, infB,
and 16S rRNA) was applied to these newly sequenced genomes [47]. Using these concatenated
sequences from all the sequenced NTHi a dendrogram was constructed to demonstrate the dis-
tribution of the newly sequenced isolates within the species (Fig 2).
Fig 2. Distribution of sequenced NTHi isolates.Neighbor joining dendogram of NTHi strains used in this
study. The tree is rooted with Eschericia coliMG1655 and is based on sequence comparisons of the
concatenated adk, pgi, recA, infB and 16s rRNA gene sequences, with bootstrap values of greater than 50%
of 1,000 bootstraps indicated. Also included are several non NTHi sequences; Hp (H. parainfluenzae T3T1),
HH (H. haemolyticus ATCC 33390) and theH. influenzae strains Rd KW20 and 10810.
doi:10.1371/journal.pone.0136867.g002
Protective NTHi Peptides
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Identification of core SEPs present in the NTHi
Initially we identified the complement of putative SEPs in the NTHi strain 86-028NP. Such
proteins were identified based on known annotation, the presence of export signal sequences,
and their similarity to known OMPs in other species. Proteins that localize exclusively to the
periplasmic space were in general excluded. However, some proteins considered periplasmic
have been shown to be also externally expressed; for example Pal has recently been shown to be
inserted in the OM in two distinct orientations [48,49]. Thus, periplasmic proteins that might
be anchored to the OM were retained unless definitive evidence exists that they are not exter-
nally located. Each coding region was analyzed using PSORTb and PSORT [50]. Proteins with
localization signals indicating export across the cytoplasmic membrane were analyzed for
homology to experimentally determined OMPs from other organisms. Finally, those proteins
in which localization to the OM was putative were further subjected to analysis for structural
motifs indicative of membrane-spanning domains. Ninety-six SEPs were identified in strain
86-028NP. This data set was then used to establish the presence of each allele in each of the 21
complete NTHi genome sequences. From these 21 complete sequences, a set of 56 NTHi core
SEPS was identified (Table 2). Using all of the available genome and stand-alone gene
sequences, the sequence conservation of each individual OMP gene was determined.
Molecular modeling to assess surface-exposed regions of the SEPs
The core SEPs s fall into three main structural categories, β-barrel, α-helix and amorphous.
The majority of OMPs that are embedded in the membrane adopt the β -barrel structure while
the remaining have an α-helix based structure. The OMPs that are either secreted or bound to
the outer membrane by a small lipophilic tail are more amorphous, often with no clearly
defined common structural features. Our previous studies focused on HxuC, a defined OMP
with the β -barrel conformation. In the outer membrane, such proteins fold to create a barrel-
like structure with a core, or plug, which can be shifted to allow ingress of a transported mole-
cule (Fig 3) [51,52]. Referred to as “gated porins”, these OMPs have been the focus of numer-
ous X-ray crystallization studies. Since they are structurally constrained, it is possible to both
map the NTHi OMPs to those with known crystal structure and to use computer assisted
molecular modeling algorithms to determine the potential externally-exposed loops. In some
cases an external loop is small, comprising one or two residues while other loops are longer
and show variable degrees of sequence heterogeneity. The proposed structure of HxuC is
shown to demonstrate the topography and location of the OM loops (Fig 3). Adjacent to it are
two sequence alignments that correspond to the indicated loops (for simplicity, only 5 genome
sequences are included). Loop 8 is highly heterologous and thus does not constitute a good
candidate for further study (Fig 3). In contrast loop 6 is conserved and satisfies our criteria for
selection as a suitable peptide motif for generation of antisera. Loop 6 corresponds to the pro-
tective peptide HxuC2 described above. Similarly, the OMPs determined to have the α-helix
conformation were mapped where possible to the conserved residues of OMPs in other species
that have deduced crystal structures. OMPs which are loosely attached to the membrane have
proven more difficult to map. To determine potentially exposed regions on these OMPs, we
utilized numerous molecular prediction algorithms to identify potential transmembrane and
exposed residues. These are usually based on hydrophobicity/hydrophilicity plots and periodic-
ity of residues in these regions. Such analyses can be used to potentially identify regions of
interest without providing an elaborated structure as shown for NTHI1734m (Fig 3). Of the 56
core OMPs, 24 appear to have the β-barrel structure and four the α-helix structure while the
rest are amorphous structures anchored to the membrane by a polypeptide tail. To date, 41 of
the core OMPs have been sufficiently modeled to identify surface exposed peptide motifs.
Protective NTHi Peptides
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Table 2. Core SEPs of the NTHia.
86-026NP locus Gene designation Rd KW20 locus Gene description Probable Typeb
NTHI0579 ytfL HI0452 Putative hemolysin (probable inner membrane) α-helix
NTHI0576 HI0449 Conserved hypothetical protein Amorphous
NTHI0560 comE HI0435 Outer membrane secretin ComE Amorphous
NTHI0522 ompP1 HI0401 Outer membrane protein P1 β-barrel
NTHI0509 yeaY HI0389 Slp family OM lipoprotein Amorphous
NTHI0501 pal HI0381 Peptidoglycan associated OMP Amorphous
NTHI0486 pilF HI0366 Transformation and Tfp-related protein PilF Amorphous
NTHI0449 oapB HI0331 Opacity associated adhesion protein B Amorphous
NTHI0448 oapA HI0330 Opacity associated adhesion protein A α-helix
NTHI0409 pilA HI0299 Type II secretory pathway, major prepilin PilA Amorphous
NTHI0370 hxuB HI0263 Heme-hemopexin utilization protein B β-barrel
NTHI0369 hxuC HI0262 Heme-hemopexin utilization protein C β-barrel
NTHI0363 nlpB HI0256 OMP assembly complex subunit NlpB/BamC Amorphous
NTHI0354 hap HI0247 Adhesion and penetration protein precursor β-barrel
NTHI0353 HI0246 Putative lipoprotein Amorphous
NTHI0338 mltF HI0232 Membrane-bound lytic murein transglycosylase F Amorphous
NTHI0303 nucA HI0206 5’-nucleotidase NucA Amorphous
NTHI0267 ompE HI0178 Adhesin protein E Amorphous
NTHI0266 bamD HI0177 OMP assembly complex subunit BamD Amorphous
NTHI0252 yajG HI0162 Putative lipoprotein Amorphous
NTHI0225 ompP2 HI0139 Outermembrane protein P2 β-barrel
NTHI0220 HI0134 Putative OMP assembly protein β-barrel
NTHI0205 mltA HI0117 Membrane-bound lytic murein transglycosylase A Amorphous
NTHI0202 hemR HI0113 Probable TonB-dependent heme receptor β-barrel
NTHI1987 yccT HI1681 Conserved hypothetical protein Amorphous
NTHI1957 lppC HI1655 Lipoprotein LppC Amorphous
NTHI1954 spr HI1652 Lipoprotein Spr, probable murein endopeptidase Amorphous
NTHI1930 HI1236m Conserved hypothetical protein β-barrel
NTHI1668 tdeA HI1462 Outer membrane efflux porin TdeA β-barrel
NTHI1794m HI1369 Probable TonB-dependent transporter β-barrel
NTHI1473 lpp HI1579 15 kDa peptidoglycan-associated lipoprotein α-helix
NTHI1435 lolB HI1607 OM lipoprotein insertion protein LolB Amorphous
NTHI1390 hup HI1217 Heme utilization protein β-barrel
NTHI1387 HI1215 Conserved hypothetical protein Amorphous
NTHI1342 olpA HI1174m Probable surface adhesion OlpA β-barrel
NTHI1332 ompP5 HI1164 Outer membrane protein OmpP5 β-barrel
NTHI1262 HI1098m Conserved hypothetical protein Amorphous
NTHI1171 ompU HI0997m Putative OM protein OmpU β-barrel
NTHI1169 tbp2 HI0995 Transferrin binding protein 2 Amorphous
NTHI1168 tbp1 HI0994 Transferrin binding protein 1 β-barrel
NTHI1164 igA1 HI0990 IgA1 protease β-barrel
NTHI1140 HI0966 Conserved hypothetical protein β-barrel
NTHI1133 ycfL HI0960 Putative lipoprotein YcfL Amorphous
NTHI1101 HI0930 Putative lipoprotein Amorphous
NTHI1091 lptE HI0922 LPS assembly OM complex LptDE component β-barrel
NTHI1084 bamA HI0917 OM protein assembly factor BamA β-barrel
NTHI1005 smpA HI0838 OMP assembly complex subunit SmpA/BamE Amorphous
(Continued)
Protective NTHi Peptides
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These include 16 of the β-barrels, 2 of the α-helical proteins and 23 of the amorphous struc-
tures (Table 2). Combining putative structure with the sequence alignments allows identifica-
tion of conserved putatively surface exposed regions (S1 Table and S2 Table).
Characterization of protective epitopes
Although the structural mapping indicates conserved surface exposed regions, determination
of whether these regions are antibody accessible in vivo requires empirical analysis. From the
Table 2. (Continued)
86-026NP locus Gene designation Rd KW20 locus Gene description Probable Typeb
NTHI0921 mltC HI0761 Membrane bound-lytic murein transglycosylase C Amorphous
NTHI0889 lptD HI0730 LPS assembly OM complex LptDE, protein LptD β-barrel
NTHI0849 mlaA HI0718 Outer membrane lipid asymmetry protein MlaA α-helix
NTHI0840m hgpC HI0712 Hemoglobin-haptoglobin utilization protein C β-barrel
NTHI0821 tpsA HI0698 Two-partner secretion system protein β-barrel
NTHI0820 tpsB HI0696 Two-partner secretion system protein β-barrel
NTHI0816 hel HI0693 Outer membrane protein P4 Amorphous
NTHI0811 glpQ HI0689 Glycerophosphodiesterase Amorphous
NTHI0782 hgpB HI0661 Hemoglobin-haptoglobin utilization protein B β-barrel
a Proteins were initially identified as putative members of the SEP complement using PSORT and PSORTb analysis of cellular localization of predicted
protein sequences and/or due to homology to known OM localized proteins. Lists were narrowed by excluding SEPs not conserved across the sequenced
NTHi isolates and removal of proteins that lacked a strong probability of being localized to the outer membrane and having surface exposed residues.
b Probable structure based on modeling. PRED-TMBB and BOMP (β-barrel), TMHMM (α-helix), amorphous for proteins that fit neither model or have
components of both. Bolding indicates proteins that have been modelled and for which conserved peptideshave been identified (see S1 Table).
doi:10.1371/journal.pone.0136867.t002
Fig 3. Outer membrane loops of an NTHi SEP. 3D computer-predicted spatial topography of the gated TonB-dependent porin HxuC. The ribbon area
corresponds to the external membrane embedded barrel. Also shownare surface exposed external loops. Arrows point to two specific loops designated OM
loops 6 and 8. Alignments of both loop regions from five NTHi strains are shown. OM loop 8 is highly heterologous while OM loop 6 is conserved.
doi:10.1371/journal.pone.0136867.g003
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sequence alignments, 5 external OM loops that showed conservation and that were a minimum
of 10 amino acid residues in length were selected. The 5 selected epitopes were in addition to
the 5 from HxuC peptides examined above. The 5 new epitopes were from 4 different proteins
ComE, Hel, TdeA and OmpU and were designated respectively ComE1, Hel1, Hel2, TdeA1
and OmpU1 (Table 2)
Each of these five epitopes was used in our immunization protocol. The TdeA1 peptide did
not induce an antibody titer sufficient to proceed with further study of that antigen. Antisera
raised to the OmpU1 peptide did not provide a significant protective effect in the infant rat
model. Five of 9 infant rats in the OmpU1-antisera treated cohort and 9 of 10 infant rats in the
control cohort had detectable bacteremia (P = 0.14). Seven of 10 infant rats pretreated with
antiserum raised to ComE1 failed to develop bacteremia (Fig 4A). While the rate of bacteremia
of the anti-ComE1 treated group was significantly lower than the rate for the PBS treated
group (P = 0.0031) it did not significantly differ from the pre-immune serum treated group
(P = 0.0698) probably to a small cohort size in the latter group (Fig 4A). However, the bacter-
emic titer in the anti-ComE1 antiserum cohort was significantly lower that seen in either of the
control groups (Fig 4B). Antiserum raised to the Hel1 was significantly protective when given
to infant rats 24 hours prior to challenge with NTHi strain R2866. While all rats pretreated
with either PBS or the pre-immune serum had detectable bacteremia 24 hours after infection 5
of 10 animals pretreated with anti-Hel1 antiserum were abacteremic (P = 0.0325) (Fig 4C).
Bacteremic titers were also significantly lower in those rats pretreated with anti-Hel1 antiserum
than those rats pretreated with either PBS or pre-immune serum (Fig 4D). Antiserum raised to
the Hel2 peptide gave similar results to those seen for Hel1 (data not shown).
Discussion
There currently are no vaccines licensed for prevention of infection caused by NTHi. Although
several potential vaccine candidates against NTHi have been evaluated. robust cross protection
against NTHi strains has not been observed. For example the H. influenzae protein D compo-
nent of the pneumococcal vaccine has demonstrated a 35% protection rate in a clinical trial
[25]. From our studies protein D (encoded by glpQ) exhibits multiple variant residues among
NTHi strains. This may account for the low protection rate. Alternatively, expression of protein
D may vary among different NTHi strains. Thus, failure of previous vaccine candidates may
arise in part from problems of target protein conservation and/or biological accessibility. In
our study we sought to obviate the problem of lack of conservation. An initial step in this study
was to identify the conserved core SEPs shared by all the NTHi. Most NTHi strains possessed
approximately 90 genes encoding SEPs. Of these, several are either distinct to a particular iso-
late or restricted to a few isolates, and are thus unsuited as vaccine candidates. For example, the
Hmw1A, Hmw1B, Hmw2A, Hmw2B, HgpA, HgpD and HgpE proteins are common among
the NTHi, but not conserved in all [53,54]. Clearly, a large set of genomic sequences is required
to exclude common, yet non-conserved proteins. From the 21 genomically sequenced, diverse
NTHi isolates we have narrowed the core set of SEPs to 56 proteins. As more genomic
sequences become available it is possible that this number may decrease further. However,
based on our selection of strains previously characterized to represent the genetic breadth of
the species, the number of genomes sequenced, and the conservation of core genes predicted
by computer based models [55], the chance of elimination of a gene with a further increase in
the number of sequenced genomes is possible but unlikely. Thus, we propose that 56 genes
encode the core SEPs of the NTHi. The conservation across the species of these core SEPs sug-
gests they are required for the survival and/or cellular fitness of the NTHi. Thus, finding
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conserved regions of these proteins was not surprising and probably represents their essential
functionality for NTHi survival. Of these 56 core SEPs the structures of 41 have been modeled.
Initially, putative externally exposed loops were selected from the modeled SEPs based on
the length of the conserved region. Regions containing greater than 10 amino acids were
Fig 4. Protection afforded by antisera raised against ComE and Hel derived peptides in the infant rat model of NTHi bacteremia. Panel A)
Percentage of infected infant rats pretreated with anti-ComE1 antiserum with detectable bacteremia 24 hours after infection. Twenty-four hours prior to
infection cohorts of infant rats were pretreated with phosphate-buffered saline (PBS; cohort of 9 rats), pre-immune serum (PIS; cohort of 9 rats) or anti-
ComE1 antiserum (ComE1; cohort of 10 rats). Using Fisher’s exact test to compare percentages of bacteremic pups P = 0.0031 for PBS vs ComE1 and
P = 0.0698 for PIS vs ComE1. Panel B) Bacteremic titers in infant rats pretreated with anti-ComE1 antisera 24 hours after infection. Filled dots represent the
bacteremic titer in each individual animal in a cohort. The unfilled dot represents the average bacteremic titers in all members of the cohort. Values of 1 or
below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to compare bacteremic titers (mean ±SD) P = 0.07 for PBS vs PIS,
P = 0.0002 for PBS vs ComE1 and P = 0.01 for PIS vs ComE1. Panel C) Percentage of infected rats pre-treated with anti-Hel1 antisera with detectable
bacteremia 24 hours after infection. Twenty-four hours prior to infection cohorts of infant rats were pretreated with phosphate-buffered saline (PBS; cohort of
10 rats), pre-immune serum (PIS; cohort of 9 rats) or anti-Hel1 antiserum (Hel1; cohort of 10 rats). Using Fisher’s exact test to compare percentages of
bacteremic pups P = 0.0325 for both PBS vs Hel1 and PIS vs Hel1. Panel D) Bacteremic titers in infant rats pretreated with anti-Hel1 antiserum with
detectable bacteremia 24 hours after infection. Filled dots represent the bacteremic titer in each individual animal in a cohort. The unfilled dot represents the
average bacteremic titers in all members of the cohort. Values of 1 or below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to
compare bacteremic titers (mean ±SD) P = 0.15 for PBS vs PIS, P = 0.0003 for PBS vs Hel1 and P = 0.0005 for PIS vs Hel1.
doi:10.1371/journal.pone.0136867.g004
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selected as possible linear epitopes. Over 80 such regions that showed complete identity were
identified (S2 Table). The presence of conserved external loops suggests that these regions play
a critical role in protein function. Alternatively, variations in these regions may be unnecessary
if the regions are not available to the human immune system.
Almost 200 peptides from the core SEPs satisfied our initial screening criteria. While com-
puter-assisted modeling and bioinformatics may identify putative exposed regions, antibody
accessibility in vivomust be confirmed empirically. A number of confounding factors may ren-
der a putative epitope inaccessible. Gene regulation, spatial orientation of the loop itself, shield-
ing by other loops and steric hindrance can render potential targets antibody inaccessible. To
empirically determine in vivo antibody accessibility, an animal model was utilized. Of the 200
candidate peptides, 10 have been analyzed to determine their biological accessibility (Table 1).
Initially, the 5 peptides targeting regions of HxuC were analyzed. Peptides HxuC1 and
HxuC2 generated antisera that were protective while HxuC3, HxuC4 and HxuC5 did not.
Since these experiments were performed, new sequencing data have revealed that HxuC5 has
two variant residues in the middle of the loop. In two of the newer sequences an isoleucine resi-
due is substituted for a methionine residue, and in a third sequence a lysine is substituted for
an arginine. The protein in strain R2866 has both the methionine and arginine residues. Thus,
sequence heterogeneity cannot explain the lack of protection observed by antisera raised to
peptide HxuC5.
Based on the availability of genomic sequences at the time of these studies, all of the peptides
(with the exception of ComE1, Hel2 and TdeA) were designed to loops that were absolutely
conserved across the NTHi. Peptides ComE1, Hel2 and TdeA were designed to match the
inherent variability of the corresponding OM loop. Each had a single variant residue. To
address this heterogeneity, two peptides were made for each sequence and an equimolar mix-
ture of each was used to inoculate the adult rats. The outer membrane loop that the ComE1
peptide was designed from was estimated at 33 amino residues. From this a 20 residue region
was selected based on maximal immunogenicity predicted by the AbDesigner algorithm [41].
Similarly the 20-mer peptide Hel1 was selected from an estimated exposed loop of 27 residues.
Antisera raised to both of the Hel peptides and the ComE1 peptide were protective. Analysis of
the specific immunogenicity of each peptide was beyond the scope of the present study.
It is unknown why only certain peptides stimulate protective antisera. Of the five synthetic
peptide antigens targeting the HxuC protein, only two provided significant protection. Since
the structure of the gated porins is well defined and the target appears surface exposed, steric
hindrance may interfere with antibody accessibility to the non-protective loops. The same may
also be true for antisera raised to the OmpU1 peptide since OmpU has a known β-barrel struc-
ture. Unlike HxuC, ComE and Hel are both amorphous structures with a suspected membrane
anchor. In situ, the majority of the protein would be surface exposed. Selection of peptides
from these sequences was based primarily on regions of predicted α-helices. While each pep-
tide was modeled to be surface exposed, the clear protection against NTHi challenge in the
infant rat provides empirical proof of surface exposure.
In summary, NTHi is an important public health burden without an obvious vaccine target.
We hypothesize that likely successful targets may be regions of proteins that are both conserved
and antibody available in vivo. Screening of well-characterized NTHi genome sequences identi-
fied 56 core SEPs present in all strains. These proteins were modeled to identify regions which
may be available on the outer surface. Antisera raised to 10 externally exposed, conserved pep-
tides were tested for their in vivo passive protective capacity. Of the 10 peptides, 5 induced sera
that provided protection. These data provide proof of principle that certain conserved peptides
may be antibody available and may be useful components of a vaccine. Additionally, these data
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provide a foundation to identify many other peptide targets for antibody production to protect
against NTHi infection.
Supporting Information
S1 Table. Potential surface-exposed, highly conserved peptides of the NTHi.
(XLSX)
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